SML3799

Nilotinib

≥98% (HPLC)

• Synonym(s): 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide, 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide, AMN 107, AMN107
• Empirical Formula (Hill Notation): C₂₈H₂₂F₃N₇O
• CAS Number: 641571-10-0
• Molecular Weight: 529.52
• MDL number: MFCD09833716
• UNSPSC Code: 12352200
• NACRES: NA.21

Properties

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (Warmed)
• storage temp.: 2-8°C
• SMILES string: FC(F)(F)c1cc(cc(c1)NC(=O)c3cc(c(cc3)C)Nc4nc(ccn4)c5cnccc5)[n]2cnc(c2)C
• InChI: 1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
• InChI key: HHZIURLSWUIHRB-UHFFFAOYSA-N

Description

Biochem/physiol Actions

Nilotinib (AMN107) is an orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor that is 10-30-fold more potent than imatinib. Nilotinib is used to treat Philadelphia chromosome (Ph+)-positive chronic myelogenous leukemia (CML). Nilotinib reduces midbrain Bcr-Abl autophosphorylation, amyloid-β levels, and neuronal loss, as well as improves autophagosome clearance and reverses cognitive deficits in the Tg2576 transgenic mouse model of Alzheimer’s disease.

Orally available, selective and potent ATP-competitive wild-type and mutant Bcr-Abl kinase inhibitor

Safety Information

• pictograms: GHS08
• signalword: Danger
• hcodes: H372,H413
• pcodes: P260 - P264 - P270 - P273 - P314 - P501
• Hazard Classifications: Aquatic Chronic 4 - STOT RE 1
• target_organs: Liver,Kidney,gallbladder
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk_germany: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable